3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 4
3
Phase 2
1
Status
Completed
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Dermatologic
1
Conditions
Lung Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neurofibromatoses
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hydrocephalus
1
Headache
1
Gallbladder Neoplasms
1
Female Breast Carcinoma
1
Epilepsy
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Edema
1
Abdominal Neoplasms
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Sevoflurane
×
Clear all
NCT01975064
2022-12-14
CAN
Uppsala University
Phase 4
Completed
5,774 enrolled
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled
NCT00575354
2008-04-21
CSIABTEC
Nanjing Medical University
Phase 4
Completed
500 enrolled